Equillium Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
EQ Nasdaq 2834 https://www.equilliumbio.com/home/default.aspx

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Equillium Inc

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Apr 3rd, 2024 12:00 pm
5 Stocks That More Than Doubled in Q1 With More Gains Ahead - Apr 1st, 2024 1:52 pm
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis - Apr 1st, 2024 12:00 pm
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates - Mar 25th, 2024 9:10 pm
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights - Mar 25th, 2024 8:01 pm
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference - Mar 22nd, 2024 12:00 pm
Individual investors account for 41% of Equillium, Inc.'s (NASDAQ:EQ) ownership, while insiders account for 20% - Mar 22nd, 2024 10:27 am
The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark - Mar 4th, 2024 10:25 am
5 Stocks That More Than Doubled in February - Mar 1st, 2024 2:29 pm
5 Top-Ranked Stocks That Have More Than Doubled Year to Date - Feb 23rd, 2024 2:08 pm
Even after rising 85% this past week, Equillium (NASDAQ:EQ) shareholders are still down 85% over the past three years - Feb 9th, 2024 10:57 am
15 Cash-Rich Penny Stocks Hedge Funds Are Buying - Jan 29th, 2024 9:07 am
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease - Dec 21st, 2023 1:00 pm
EQ Bank Card launches in Québec as Carte Banque EQ - Nov 20th, 2023 4:23 pm
Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology - Nov 13th, 2023 2:00 pm
Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates - Nov 8th, 2023 9:01 pm
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology - Nov 6th, 2023 1:00 pm
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis - Oct 24th, 2023 4:30 pm
Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology - Oct 19th, 2023 12:00 pm
Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium - Oct 16th, 2023 12:00 pm